Ultragenyx Pharmaceutical (RARE) Preferred Stock Liabilities (2013)

Ultragenyx Pharmaceutical's (RARE) quarterly Preferred Stock Liabilities came in at $73.9 million in Q4 2013.

Ultragenyx Pharmaceutical (RARE) Preferred Stock Liabilities (2013) Analysis & Trends

Ultragenyx Pharmaceutical (RARE) has 1 years of Preferred Stock Liabilities data on file, last reported at $73.9 million in Q4 2013.

On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $73.9 million in Q4 2013; TTM through Dec 2013 was $73.9 million, a N/A change from a year earlier, with the FY2013 full-year figure at $73.9 million, up 97.37% from the prior year.
Preferred Stock Liabilities for Q4 2013 stood at $73.9 million.
Over the last five years, Preferred Stock Liabilities for RARE reached as high as $73.9 million in Q4 2013 and fell as low as $73.9 million in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Ultragenyx Pharmaceutical	2.72 Bn	2.31 Bn	106.00 Mn	-

Download Data

Date	Value
Dec 31, 2013	73.93 Mn